NCT02651376View on ClinicalTrials.gov

Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

August 31, 2017

Conditions
Human Immunodeficiency VirusImmunodeficiency
Interventions
COMBINATION_PRODUCT

Conventional plus AAIT

Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER

NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients | Biotech Hunter | Biotech Hunter